Pediatric Patients with Neurofibromatosis Type 1 and its Association with Intellectual Impairment

Article Sidebar

PDF
Published: Aug 30, 2022
DOI: https://doi.org/10.47191/ijmscrs/v2-i8-32
Keywords:
.

Main Article Content

Diana Cecilia Miranda Torres
Universidad Autónoma de Guadalajara
Hamilton Miranda Torres
Universidad Autónoma de Guadalajara
Aleza Imara Salgado Hernandez
Universidad Autónoma de Baja California
Carlos Andrés López Martinez
Universidad Autónoma de Ciudad Juárez
Jorge Francisco Martínez Hernández
Universidad Guadalajara LAMAR
Jesica Jazmín Preciado López
Universidad Guadalajara LAMAR

Abstract

Today Neurofibromatosis type 1 belongs to a genetic disorder in which there is a mutation of a gene that is on chromosome 17 which will cause at some point in the patient's life the development and growth of tumors in the central nervous system or even outside it. Epidemiologically it is known that there is no predilection for sex or person, but it is known and common, that the onset of presentation of symptoms is given after birth, for this reason, it is a disorder that occurs more frequently in children, it is important to recognize the disorder to be able to attend to the complications that occur with the evolution of the disease, remembering that a specific treatment is not known exactly. It is considered necessary the integral attention to the multiple complications that could come present, which mentions some of the most serious are: Musculoskeletal disorders, as well as presenting skin problems, being frequent presentation in the first year of life. Eye problems, learning problems at school age and even worse prognosis can reach a degree of mental retardation.

Article Details

How to Cite
Torres, D. C. M. ., Torres, H. M. ., Hernandez, A. I. S. ., Martinez, C. A. L. ., Hernández, J. F. M. ., & López, J. J. P. . (2022). Pediatric Patients with Neurofibromatosis Type 1 and its Association with Intellectual Impairment. International Journal of Medical Science and Clinical Research Studies, 2(08), 880–884. https://doi.org/10.47191/ijmscrs/v2-i8-32
Issue
Vol. 2 No. 08 (2022): Volume 02 Issue 08 August 2022
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Papadakis A. Maxine, Stephen J. Mcphee. Current. cmdt. Medical diagnosis and treatment. Ed. el Sevier. Editorial McGraw-Hill. 2015.

II. A. Duat Rodríguez, G.Á. Martos Moreno, Y. Martín Santo-Domingo, A. Hernández Martín, J.M. Espejo-Saavedra Roca, M.L. Ruiz-Falcó Rojas, J. Argente. Phenotypic and genetic features in neurofibromatosis type 1 in children. An Pediatr (Barc). 2015; 83(3):173-182.

III. huijbregts s, outfielder m, rombouts s, swaab h, verbist b, arkink e et al. cerebral volumetric abnormalities in neurofibromatosis type 1: associations with parent ratings of social and attention problems, executive dysfunction, and autistic mannerisms. Journal of neurodevelopmental disorders. 2015; 7(1).

IV. Bonita P. Klein-Tasman, Kelly M. Janke , Wen Luo , Christy L. Casnar , Scott J. Hunter , James Tonsgard , Pamela Trapane , Faye van der Fluit , and Lorri A. Kais. Cognitive and Psychosocial Phenotype of Young Children with Neurofibromatosis-1. J Int Neuropsychol Soc. 2014; 20(1): 88–98.

V. Miladys Orraca-Castillo, Nancy Estévez-Pérez and Vivian Reigosa-Crespo. Neurocognitive profiles of learning disabled children with neurofibromatosis type 1. Frontiers in Human Neuroscience 2014; 8: 386.

VI. Goldsmith A. Lowell, Gilchrest, Paller, Leffell, Wolf. Fitzpatrick. Dermatology in General Medicine. Ed. 8th. Editorial Médica Panamericana. 2014.

VII. Shruti Garg, MRCPsych, Jonathan Green, FRCPsych, Kathy Leadbitter, PhD, Richard Emsley, PhD, Annukka Lehtonen, DPhil, PhD, D. Gareth Evans, MD, FRCP, and Susan M. Huson, MD, FRCP. Neurofibromatosis Type 1 and Autism Spectrum Disorder. Pediatrics 2013; 132: e1642–e164.

VIII. Zhao X, Li J, Shi L, Yang L, Wu Z, Zhang D. Surgical Treatment of Dystrophic Spinal Curves Caused by Neurofibromatosis Type 1. MD Journal. 2016; 95(14):1-5.

IX. shruti garg, annukka lehtonen, susan m huson, richard emsley, dorothy trump, d gareth evans, jonathan green. Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a population-based study. Developmental Medicine & Child Neurology 2013; 55: 139–145.

X. lehtonen a, howie e, trump d, huson s. behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence. Developmental medicine & child neurology. 2012; 55(2):111-125.

XI. Author Yon Albisu. Atlas of Pediatric Dermatology. Ed. 2nd. Editorial Océano Ergon.2009.

XII. Máximo Zimerman, MaximilianJ.Wessel, Jan E. Timmermann, SofiaGranström, Christian Gerloff, Victor F. Mautner, Friedhelm C. Hummel. Impairment of Procedural Learning and Motor Intracortical Inhibition in Neurofibromatosis Type 1 Patients. EBioMedicine 2 (2015); 1430–1437.

XIII. Danielle de Souza Costa, Jonas J. de Paula, Antonio M. Alvim-Soares Jr, Patrícia A. Pereira, Leandro F. Malloy-Diniz, Luiz O. C. Rodríguez, Marco A. Romano-Silva and Débora M. de Miranda. COMT Val 158 Met Polymorphism Is Associated with Verbal Working Memory in Neurofibromatosis Type 1. Frontiers in Human Neuroscience 2016; 10: 334.